FDA Issues Draft Guidance Allowing Cell and Gene Therapy Developers to Rely on Prior Scientific Knowledge
The US Food and Drug Administration is issuing draft guidance that would allow cell and gene therapy developers to rely more on existing scientific knowledge instead of rebuilding the evidence base for each new treatment. The approach is aimed at serious, life-threatening rare diseases, where patient populations are often too small to support repeated studies.
The shift would amount to a more industry-friendly framework for increasingly personalized medicines and could ease development for small biotech companies working on narrowly defined mutations. The aim is to remove duplicative testing and paperwork rather than lower the clinical bar, signaling a regulator seeking to speed gene therapies without relaxing safety expectations.
From the sources (4 posts)
@axiosFDA issues industry-friendly gene therapy guidance
@martinvarsAxios cuenta hoy que la FDA va a publicar una guía para terapias celulares y génicas que permite a las empresas apoyarse más en conocimiento científico ya existente, en vez de repetir pruebas innecesarias cada vez que desarrollan un tratami
@clearpath100$QURE Timely backdrop to the HD therapy race: FDA will according to Axios today issue draft guidance letting cell & gene therapy developers lean on prior scientific knowledge instead of rebuilding the evidence base each time, explicitly a
@bfristLast week, I sat down with my friend @ScottGottliebMD and @AEI for a wide-ranging conversation on FDA modernization, pandemic preparedness, AI in medicine, public trust, and the next wave of cell and gene therapies. American medicine is at